Merida Biosciences
Dodzie Sogah currently serves as Chief Operating Officer at Merida Biosciences and holds board member positions at both Trace Neuroscience and the Cystic Fibrosis Foundation. Previously, Dodzie Sogah was a Venture Partner and Entrepreneur In Residence at Third Rock Ventures and acted as Interim Chief Operating Officer at Septerna. Dodzie Sogah earned a PhD in Cellular and Developmental Biology from Harvard Medical School and an AB/MA in Biochemical Sciences and Molecular and Cellular Biology from Harvard University.
This person is not in any teams
This person is not in any offices
Merida Biosciences
Merida Biosciences is a biotechnology company pioneering a new class of precision therapeutics designed to selectively and durably eliminate pathogenic antibodies that drive disease. The company is advancing a robust pipeline to precisely eliminate the root cause of multiple autoimmune and allergic conditions that are inadequately treated today. Its lead program is designed to specifically and rapidly clear the pathogenic autoantibodies that cause Graves' disease, an autoimmune disorder that affects the thyroid gland. Merida was publicly launched in April 2025 and is based in Cambridge, MA. For more information about Merida, visit www.meridabio.com.